420 related articles for article (PubMed ID: 31281165)
21. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
22. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
23. The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells.
Gershovich PM; Karabelskii AV; Ulitin AB; Ivanov RA
Biochemistry (Mosc); 2019 Jul; 84(7):695-710. PubMed ID: 31509722
[TBL] [Abstract][Full Text] [Related]
24. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
25. [Development of innovative T-cell immunotherapy for hematological malignancies].
Ochi T
Rinsho Ketsueki; 2019; 60(7):824-833. PubMed ID: 31391373
[TBL] [Abstract][Full Text] [Related]
26. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
27. T cell senescence and CAR-T cell exhaustion in hematological malignancies.
Kasakovski D; Xu L; Li Y
J Hematol Oncol; 2018 Jul; 11(1):91. PubMed ID: 29973238
[TBL] [Abstract][Full Text] [Related]
28. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
29. CAR-T Cell Therapies From the Transfusion Medicine Perspective.
Fesnak A; Lin C; Siegel DL; Maus MV
Transfus Med Rev; 2016 Jul; 30(3):139-45. PubMed ID: 27067907
[TBL] [Abstract][Full Text] [Related]
30. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
[TBL] [Abstract][Full Text] [Related]
31. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
Date V; Nair S
Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
[TBL] [Abstract][Full Text] [Related]
32. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.
Hovhannisyan L; Riether C; Aebersold DM; Medová M; Zimmer Y
Mol Cancer; 2023 May; 22(1):82. PubMed ID: 37173782
[TBL] [Abstract][Full Text] [Related]
33. Synthetic T cell receptor-based lymphocytes for cancer therapy.
Getts D; Hofmeister R; Quintás-Cardama A
Adv Drug Deliv Rev; 2019 Feb; 141():47-54. PubMed ID: 30981835
[TBL] [Abstract][Full Text] [Related]
34. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
37. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
38. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.
Jogalekar MP; Rajendran RL; Khan F; Dmello C; Gangadaran P; Ahn BC
Front Immunol; 2022; 13():925985. PubMed ID: 35936003
[TBL] [Abstract][Full Text] [Related]
39. Current Progress in CAR-T Cell Therapy for Solid Tumors.
Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
